Latest News & Updates

Sentry team to participate in the 2019 Susan G. Komen Race for the Cure ®

This Saturday, April 27th, 2019 several Sentry BioPharma Services team members will be proudly participating in the 2019 Komen Central Indiana Race for the Cure ®.  Over the years this event has raised more than $2 billion dollars to help fund research, education, screening and treatment. ...

Monday, April 22, 2019 | Read More

Biologics Contribute to Growth in Pharma Products Cold-Chain Market

In its September issue, Pharmaceutical Commerce details the previous and expected contributions of biologic products to its forecast of cold-chain market growth predicting sales of cold-chain drugs and biologics will outpace overall industry growth through 2022. It is reported that “as of 2018, global...

Wednesday, September 12, 2018 | Read More

FDA Researchers Explore Fundamental Chemical Reaction that Could Threaten the Quality of Therapeutic Protein Products

In a recent news release the FDA described research it has conducted regarding detection of protein carbonylation, an oxidative reaction that may occur in therapeutic protein drug products during manufacture, storage, use, and transport potentially causing structural alterations and threatening stability,...

Tuesday, September 11, 2018 | Read More


David S. Cardin - Director of Quality Assurance

David S. Cardin

Mr. David S. Cardin is the Director, Quality Assurance of Sentry BioPharma Services, Inc. Mr. Cardin joined the Sentry team in 2020. Mr. Cardin has over twenty-six (26) years of experience in the medical device and pharmaceutical industries with roles in Quality, Sterilization/Sterility Assurance, and Operations. With over twenty-five (25) years in various management roles, Mr. Cardin’s experience includes  interacting with government and regulatory agencies, validation, and process and organizational development.

Mr. Cardin received his BA in Biological Science with an emphasis in Genetics and Molecular Biology from California State University, Fullerton.